Tamantha K. Stutchbury

Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma

David R. Croucher, D. Croucher, F. Al-Ejeh, 2007, Molecular Cancer Therapeutics.

Preclinical evaluation of Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma

D. Croucher, F. Al-Ejeh, M. Links, 2007 .

Preclinical evaluation of 213 Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma

D. Croucher, F. Al-Ejeh, M. Links, 2007 .

Understanding the assistive technology needs of people over 55: The future of mobility aids

L. Moxham, V. Traynor, Victoria Ikutegbe, 2019, Australasian journal on ageing.

Development and assessment of novel all-in-one parenteral formulations with integrated anticoagulant properties for the concomitant delivery of 5-fluorouracil and calcium folinate

M. Ranson, K. Vine, A. Gamble, 2009, Anti-cancer drugs.

Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles

M. Ranson, K. Vine, P. Clingan, 2011, Anti-cancer drugs.

Challenge-led interdisciplinary research in practice: Program design, early career research, and a dialogic approach to building unlikely collaborations

Victoria Ikutegbe, Tamantha K. Stutchbury, Nicole L Michielin, 2018, Research Evaluation.

Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles

M. Ranson, K. Vine, P. Clingan, 2011, Anti-cancer drugs.